CN Patent

CN112933059A — 一种布立西坦片剂的干法制粒工艺

Assigned to Zhejiang Anglikang Pharmaceutical Co ltd · Expires 2021-06-11 · 5y expired

What this patent protects

本申请提供一种布立西坦片剂的干法制粒工艺，属于细粒状的丸剂、锭剂或片剂医药配置品技术领域。由干法制粒而成的片芯与包衣组成，所述的药物片芯包含15%‑30%的布立西坦，包衣占总制剂的4%‑8%。本发明布立西坦片剂可用于治疗4岁及其以上患者的部分性癫痫发作，该干法制粒工艺可显著降低生产成本，大大提高崩解性和溶出度，易于放大投产，有利于制药企业生产。

USPTO Abstract

本申请提供一种布立西坦片剂的干法制粒工艺，属于细粒状的丸剂、锭剂或片剂医药配置品技术领域。由干法制粒而成的片芯与包衣组成，所述的药物片芯包含15%‑30%的布立西坦，包衣占总制剂的4%‑8%。本发明布立西坦片剂可用于治疗4岁及其以上患者的部分性癫痫发作，该干法制粒工艺可显著降低生产成本，大大提高崩解性和溶出度，易于放大投产，有利于制药企业生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN112933059A
Jurisdiction
CN
Classification
—
Expires
2021-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Zhejiang Anglikang Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.